Navigation Links
NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
Date:6/3/2008

with stage IIb, III or IV non-small

cell lung cancer (NSCLC) unsuitable for radical therapy" (Abstract number

3037):

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF- will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
5. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
8. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
9. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
10. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Scientists at NYU Langone Medical Center have found a ... process for turning adult cells into so-called pluripotent stem ... Using the new technique in mice, the researchers increased ... cells by more than 20-fold compared with the standard ... and thus should generally accelerate research aimed at using ...
(Date:9/19/2014)... Florida , September 19, 2014 ... medical technology, development of emerging drug systems and advanced ... Benton, Dickinson and Company (NYSE: BDX ), ... Regado Biosciences Inc. (NASDAQ: RGDO ), Sangamo ... Inc. (NASDAQ: HOLX) Pressure BioSciences, Inc. (OTCQB: ...
(Date:9/19/2014)... 2014 Barnhardt Manufacturing Company ... its Organic Cotton . The USDA Certified Biobased ... biobased ingredients meets or exceeds levels set by USDA. ... whole or in significant part of agricultural, forestry, or ... Organic cotton to be immediately identified as a USDA ...
(Date:9/19/2014)... , September 19, 2014 The ... Spain , available today on PharmaBoardroom.com ... the Eurozone crisis that rocked the Spanish economy in 2009, ... Spanish pharma community has remained pragmatic in times of trouble. ... is still the fifth biggest European market, and the general ...
Breaking Biology Technology:NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3
... N.J., March 13 Medco Health,Solutions, Inc. (NYSE: ... sell $300,million aggregate principal amount of 6-1/8 percent senior ... amount of 7-1/8 percent,senior notes due March 15, 2018 ... Banc of America Securities LLC and Barclays,Capital Inc. are ...
... Future Generation Treatment from Abbott Shows No Thrombosis, Low ... in Preliminary Clinical Study of Thirty Patients, ABBOTT ... Lancet from ABSORB, the world,s first clinical trial of ... coronary artery,disease, demonstrated no stent thrombosis, no clinically driven ...
... BERKELEY, Calif., March 13 Nile Therapeutics,Inc. (OTC ... and,full year financial results for 2007. Participants may ... the investor relations section of,Nile,s website at ... company,s website until the next quarterly conference call., ...
Cached Biology Technology:Medco Issues $1.5 Billion of Senior Notes 2Medco Issues $1.5 Billion of Senior Notes 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 4Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3
(Date:9/18/2014)... ANTONIO, September 18, 2014 New research into the ... causes a severe hemorrhagic disease in humans similar to ... essential for CCHFV infection. This discovery has the potential ... the pathogen. , The research, reported in ... Pathogens and conducted by scientists at the Texas ...
(Date:9/18/2014)... starts a "frequent flyers" program, fruit flies surely would ... has hosted increasing numbers of fruit fly research studies. ... in April, and another is scheduled launch to the ... launch in December. , Fruit flies are biomedical research ... space. Model organisms can reveal the basis for health ...
(Date:9/18/2014)... to acquire and creatively manipulate spoken language is unique ... past 6 million years of human evolution to make ... best candidate gene we now have," says Wolfgang Enard, ... his efforts to understand the molecular biological basis of ... The results of his latest study, undertaken in collaboration ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... the sediments of Gunica Bay, Puerto Rico, in a ... PCBs, chlordane, chromium and nickel ever measured in the ... contaminant monitoring program that began in 1986. Researchers ... Ocean Science (NCCOS) studied the reef,s ecology to help ...
... drifting herbicides do not create unintended consequences on neighboring ... researchers found a range of effects -- positive, neutral ... on old fields -- ones that are no longer ... to J. Franklin Egan, research ecologist, USDA-Agricultural Research Service. ...
... who graduated in 1978 with a degree in chemical ... Engineering. Election to the National Academy of Engineering ... Academy membership honors those who have made ... Pawlikowski is the commander, Space and Missile Systems Center, ...
Cached Biology News:Drifting herbicides produce uncertain effects 2
... jetSI-ENDO-FluoF is a fluorescein-conjugated ... emission at 520 nm), the ... reagents are used to determine ... the intracellular delivery and trafficking ...
... and Tissue Staining Kits are intended for ... of histological and cytological specimens. These kits ... manufactured by either R&D Systems or by ... the formation of the Avidin-Biotin Complex (ABC) ...
... Purification Protocols covers a wide range of ... and experienced researchers in all areas of ... from the books preface illustrates just how ... research library., The chapters introduce the theoretical ...
... TSQ Quantum Ultra defines a new standard ... analysis. It features the revolutionary Ion ... titanium skimmer with superior skimming and larger ... Its redesigned ion transfer tube lens with ...
Biology Products: